Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person David Moore
2 Reason for the notification
a) Position/status Executive Vice President, head of Corporate Development
b) Initial notification/Amendment Initial notification
3 Details of the issuer
a) Name Novo Nordisk A/S
b) LEI 549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a) Description of the financial instrument,
type of instrument,		 ADRs
  Identification code NVO
b) Nature of the transaction Purchase of ADRs
c)







 Price(s) and volume(s)







        
  Price(s) Volume(s)  
  DKK 709.25 2,500 ADRs  
       
       
d) Aggregated information
  • Aggregated volume
  • Price

2,500 ADRs
DKK 1,773,118.70
e) Date of the transaction 2024-11-18
f) Place of the transaction New York Stock Exchange

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:  
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

 Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com
Investors:  
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

 David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
Sina Meyer
+45 3079 6656
azey@novonordisk.com

 Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com		  

Company Announcement No 90 / 2024

Attachment

  • CA241119-insider-trading

Novo Nordisk (TG:NOV)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Novo Nordisk Charts.
Novo Nordisk (TG:NOV)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Novo Nordisk Charts.